Navigation Links
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Date:7/29/2008

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Three Months Ended

June 30,

2008 2007

GAAP NET INCOME $ 60,068 $ (4,308)

Cost of sales adjustments 28,892(1) 21,016(1)

Research and development adjustments - 16,500(2)

Settlement reserve - 56,000(3)

Gain on sale of investment - (5,791)(4)

Interest expense adjustment 3,750(5) -

Restructuring adjustment 1,565(6) -

Income tax adjustment (9,814)(7) (7,784)(7)

24,393 79,941

ADJUSTED NET INCOME $ 84,461 $ 75,633

BASIC ADJUSTED INCOME PER COMMON SHARE $1.25 $1.14

DILUTED ADJUSTED INCOME PER COMMON SHARE $1.13 $0.93

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 67,777 66,445

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 74,852 81,209

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets

($26.8 million in 2008; $21.0 million in 2007), and accelerated

depreciation related to restructuring ($2.1 million in 2008).

(2) To exclude charges related to payments for several research and

development collaborations.

(3) To exclude the reserve established for the minimum liabilit
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... (PRWEB) August 23, 2014 ... Partners LLC announced today that Janet B. Arrowsmith, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:8/22/2014)... This is a professional and ... Papain industry in Global and China. The report ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ... the international and Chinese situation is also offered. ...
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) ... of Appeals for the D.C. Circuit challenging the FAA’s Interpretation ... Federal Register on June 25, 2014. , The AMA ... text and intent of the FAA Modernization and Reform Act ... on any new rules or regulations regarding model aircraft that ...
(Date:8/22/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results for ... complete 2014 second quarter financial statements and MD&A have been filed on ... 30, , Six-months ended June 30, ( in CDN$,000 except ... , 2014 , 2013 Revenue , 2,459 ... profit , 56 , 1,485 , 385 ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... today that,Anthony DiTonno, President and Chief Executive Officer, ... Healthcare Unplugged Conference in New,York City on Tuesday, ... Financial Officer, will be available to respond to ...
... BETHESDA, Md., Sept. 2 Micromet, Inc.,(Nasdaq: ... company,developing novel, proprietary antibodies for the treatment of ... of,Barclay A. Phillips as Senior Vice President and ... member of the Company,s board of directors,since 2000, ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... Administration (FDA) review, the Company is initiating ... administration of REOLYSIN(R) in,combination with paclitaxel and ... (NSCLC) with K-RAS or EGFR-activated tumours. The ...
Cached Biology Technology:NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 4
(Date:8/22/2014)... 2014 Research ... the addition of the  "Biometrics Market ... their offering.       (Logo: ... technology that helps in the identification ... or behavioral features. It involves verification ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... La Jolla, CA Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats ... that cause 70 percent of all cervical cancer. ... models, HTI-1968 blocked the replication of HPV-16, HPV-18 ... Ph.D. and Thomas Broker, Ph.D., who presented the ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... been identified in sediment-laden marine environments, conditions previously believed to ... that Middle Reef part of Australia,s iconic Great Barrier ... in areas with lower levels of sediment stress. Led ... team of scientists is published today (1 August 2012) in ...
... from the Wildlife Conservation Society (WCS) and the National Research ... called an imperial cormorant with a small camera, then watched ... in 40 seconds, feeding on the ocean floor for 80 ... to the surface 40 seconds later. This is the ...
... appendages that plague many people in the winter and an ... for singles and couples alike. In a new study, scientists ... Nationwide Children,s Hospital have identified a biological mechanism that may ... of molecules and receptors on smooth muscle cells that line ...
Cached Biology News:Coral reef thriving in sediment-laden waters 2Are cold feet plaguing your relationship? 2Are cold feet plaguing your relationship? 3
... imaging system from Molecular Devices is ... for automated acquisition and analysis of ... ImageXpressULTRA is powered by MetaXpress, ... acquisition, image storage and analysis. MetaXpress ...
... Bioimager is an automated, confocal, real-time, single ... has been integrated into a single, compact ... to provide high-resolution, automated confocal imaging with ... better cell-based assays. The system allows the ...
... uses a simplified procedure and streamlines the ... kit is based on the three step ... sodium bisulfite where cytosine is converted into ... in-column desulphonation reaction eliminates several precipitation steps ...
... The DIGIVIEW line of digital x-ray detectors ... imaging device complete with 12 to 16 ... consists of a photodiode array sensor with ... models are available in low x-ray energies ...
Biology Products: